Adenoviral Vectors For Gene Therapy

1. Adenovirus Structure

2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms

3. Adenovirus Replication

4. Adenoviral Vector Construction I: Mammalian Systems

5. Adenoviral Vector Construction II: Bacterial Systems

6. Upstream Bioprocess for Adenovirus Vectors

7. Propagation of Adenoviral Vectors: Use of PER.C6™ Cells

8. Purification of Adenovirus

9. Targeted Adenoviral Vectors I: Transductional Targeting

10. Targeted Adenoviral Vectors III: Transcriptional Targeting

11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration

12. Molecular Design of Oncolytic Adenoviruses

13. Conditionally Replicative Adenoviruses—Clinical Trials

14. Innate Immune Response to Adenovirus Vector Administration In Vivo

15. Antibodies against Adenoviruses

16. Methods to Mitigate Immune Responses to Adenoviral Vectors

17. Helper-Dependent Adenoviral Vectors

18. Hybrid Adenoviral Vectors

19. Xenogenic Adenoviral Vectors

20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics

21. Adenoviral Vector Vaccines Antigen Transgene

22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen

23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer

24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer

25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease

26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease)

27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases

28. Animal Models of Gene Therapy for Cardiovascular Disease

29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy

30. Adenoviral Vectors for RNAi Delivery

31. Imaging and Adenoviral Gene Therapy

32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective

Adenoviral Vectors for Gene Therapy, Third Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research.

The fully updated and expanded third edition covers the basic biology of adenoviruses, highlights the potential use adenoviral vectors for the treatment of disease including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for vet applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine application and virotherapy, and oncolytic adenoviruses for anti-tumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.

• Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors
• Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement
• Demonstrates noninvasive imaging of adenovirus-mediated gene transfer
• Discusses utility of adenoviral vectors in animal disease models
• Considers Federal Drug Administration regulations for human clinical trials

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.